UK markets close in 3 hours 2 minutes

Vistin Pharma ASA (0RAM.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
24.30+0.40 (+1.67%)
As of 09:05AM BST. Market open.
Full screen
Previous close23.90
Open0.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range0.00 - 0.00
52-week range
Volume280
Avg. volume886
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)0.43
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Vistin Pharma ASA: First quarter 2024 financial results

    Oslo, Norway, 24th of April 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024. Revenue in the first quarter ended at MNOK 104 compared to MNOK 101 in Q1 2023. Sales volume in the quarter was up by 11% compared to Q1 2023. First quarter EBITDA ended at MNOK 20 compared to MNOK 14 in Q1 2023, representing a 45% increase. EBITDA positively affected by increased sales volume and product mix, partly offset by a one-time inventory adjustment of MNOK 7.

  • Globe Newswire

    Vistin Pharma ASA: Invitation to Q1 2024 conference call

    Oslo, Norway, 16 April 2024 Vistin Pharma ASA will release its first quarter results on Wednesday 24th of April 2024. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Wednesday 24th of April at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The first quarter conference call will be available via web and audio through the following access points: Webcast: https://edge.me

  • Globe Newswire

    Vistin Pharma ASA (VISTN) acquires minority share in CF Pharma (Hungary)

    Oslo, Norway, 4 March 2024 Vistin Pharma has aquired a 15% share in CF Pharma Kft. CF Pharma is an API CDMO located in Budapest, Hungary with a broad customer base of recognized international pharmaceutical companies. CF Pharma has a proven track record in developing and commercializing Active Pharmaceutical Ingredients (APIs). The group/company currently has five commercial APIs on the market, with another eight APIs under development. The transaction price consists of a base price and an earn-